Boehringer Ingelheim struck a $7 billion licensing deal with China's Sino Biopharmaceutical (SBP) to develop next-generation cancer treatments, the companies announced Wednesday.
Why it matters: Dealmaking momentum between Western pharma and Chinese biotechs is growing, despite new restrictions from the Trump administration.
